An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer

Trial Profile

An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Acronyms AHEAD-G202
  • Most Recent Events

    • 07 Feb 2017 Planned number of patients changed from 300 to 230.
    • 15 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top